FUNDAMENTAL AND CLINICAL STUDIES OF T-1982 (CEFBUPERAZONE) IN THE FIELD OF OBSTETRICS AND GYNECOLOGY

T-1982 (cefbuperazone), a novel cephamycin antibiotic, was fundamentally and clinically studied in the field of obstetrics and gynecology. The concentration of T-1982 in the maternal blood was highest and 135 μg/ml at the end of intravenous administration of 1.0g, then gradually decreased and was 10 μg/ml at 4 hours after administration. The half-life was 95.5 minutes. The concentration in the umbilical cord blood attained the peak of about 30 μg/ml at 30 minutes and was 10 μg/ml even at 4 hours, the half-life being 150 minutes. Of 10 cases comprising 5 with endometritis, 3 with pelveoperitonitis, 1 with pyometra and 1 with vulvar abscess, 8 cases were with mixed infections. Thirteen strains of Gram-positive bacteria, 7 strains of Gram-negative bacteria and 9 strains of anaerobic bacteria were isolated. Of these bacteria, 24 strains excluding 4 of S. faecalis and 1 of S. epidermidis were eradicated. The MICs of T-1982 against Gram-positive bacteria (10 strains) were higher than those of CPZ, CMZ, CEZ and SBPC. Particularly against S. faecalis (4 strains), both T-1982 and CMZ demonstrated the MICs of > 100 μg/ml. The MICs of T-1982 against Gram-negative bacteria (6 strains) excluding P. aeruginosa were similar to those of CPZ but lower than those of CMZ, CEZ and SBPC. Against anaerobes (9 strains), T-1982, CPZ, CMZ, CEZ and SBPC showed low MICs with no remarkable difference. Clinical response was observed in 8 (80%) of the 10 cases treated with T-1982. Two ineffective cases were with severe infections. No subjective and objective side effects nor abnormalities in hematology and hepatic and renal function were noted in any cases. From the above results, it is indicated that T-1982 may be useful in preventing fetal infections due to premature rupture and treating gynecological infections.